The immunization will be done with the drug Comirnaty JN.1, a vaccine developed by the pharmaceutical company Pfizer and adapted to the Omicron JN.1 subvariant of the virus.

In the first instance, risk groups will be considered, including older adults, people with comorbidities and minors with moderate to severe immunosuppresion.

Also pregnant women, people with Down syndrome, health care workers with potential risk and caregivers.

The MSP recommends that the booster dose should be given at least four months after the last dose received or after the infection.

The MSP will also roll out from Monday a vaccination campaign to prevent the spread of RSV (respiratory syncytial virus) to pregnant women over 18 years of age who are between 32 and 36 weeks of gestation.

The aim is to immunize infants under six months of age who will face their first season during autumn and the southern winter of 2025, when they are more susceptible to respiratory infections.

ef/arm/jcm/oo